<DOC>
	<DOCNO>NCT02171832</DOCNO>
	<brief_summary>The main objective study investigate influence mild moderate liver impairment pharmacokinetics , safety select pharmacodynamic parameter BI 1744 CL comparison control group normal hepatic function single orally inhaled administration BI 1744 CL Respimat® Inhaler .</brief_summary>
	<brief_title>Single Dose BI 1744 CL Patients With Mild Moderate Hepatic Impairment Compared Subjects With Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Healthy subject : Healthy male females accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test . The healthy subject must meet match criterion base match approach Age &gt; 21 &lt; 75 year Body Mass Index ( BMI ) &gt; 18.5 &lt; 32 kg/m2 Creatinine clearance &gt; 70 mL/min accord Cockcroft &amp; Gault Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Hepatically impaired subject : Hepatically male female impaired subject determine result screen classified Group 1 ( ChildPugh A ; ChildPugh score 56 point ) Group 2 ( ChildPugh B ; ChildPugh score 79 point ) Age &gt; 21 &lt; 75 year BMI &gt; 18.5 &lt; 34 kg/m2 Creatinine clearance &gt; 40 mL/min accord Cockcroft &amp; Gault ( hepatically impair patient ) Signed date write informed consent prior admission study accordance GCP local legislation Healthy subject meet follow criterion enter trial : Any find medical examination ( include BP [ &gt; 140 mmHg systolic &gt; 95 mmHg diastolic ] , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Relevant gastrointestinal tract surgery ( except appendectomy , herniotomy ) Diseases central nervous system ( epilepsy , seizure ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection ( e.g . include Hepatitis B C HIV ) History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator History presence allergy iodine and/or contrast agent , latent manifest hyperthyrosis allergic diathesis indocyanine green Intake drug contraindicate connection indocyanine green test Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Participation another trial investigational drug within one month previous single dose administration two month previous multiple dose administration prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke confine study site trial day Alcohol abuse ( 40 g/day male , 20 g/day female ) Drug abuse , investigator 's judgement upon review patient 's history urine screening abused substance Veins unsuited iv puncture either arm ( e.g . vein difficult locate , access puncture , vein tendency rupture puncture ) Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within 48 hour prior trial trial ) Any laboratory value outside reference range clinical relevance opinion investigator Inability comply dietary regimen study centre Subjects able understand comply protocol requirement , instruction protocolstated restriction Hepatically impaired subject meet follow criterion enter trial : Medical disorder , condition history would impair subject 's ability participate complete study opinion investigator sponsor Severe cerebrovascular cardiac disorder , e.g . myocardial infarction le 6 month prior dose , congestive heart failure New York Heart Association ( NYHA ) grade III IV , severe arrhythmia Relevant gastrointestinal tract surgery ( except appendectomy , herniotomy , oesophagean varix ) Diseases central nervous system ( epilepsy , seizure ) psychiatric disorder neurological disorder Evidence hepatic encephalopathy relate chronic liver disease &gt; grade 2 ( exclusion Number Connection Test ) History relevant orthostatic hypotension , faint spell blackout Resting heart rate awake subject 45 beat per minute ( BPM ) 100 BPM ; Systolic blood pressure 100 mmHg 160 mmHg , Diastolic blood pressure 95 mmHg Chronic relevant acute infection ( e.g . HIV ) except e.g . Hepatitis B C History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator History presence allergy iodine and/or contrast agent , latent manifest hyperthyrosis allergic diathesis indocyanine green Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial , exclude drug , patient currently take treatment hepatic concomitant disease . Change chronic medication le 4 week prior dose Participation another trial investigational drug within one month previous single dose administration two month previous multiple dose administration prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke confine study site trial day Alcohol abuse ( 60 g/day male , 40 g/day female ) Drug abuse , investigator 's judgement upon review patient 's history urine screening abused substance Veins unsuited iv puncture either arm ( e.g . vein difficult locate , access puncture , vein tendency rupture puncture ) Blood donation ( 100 mL within four week prior administration trial ) History Gastro intestinal tract bleed within past 3 month Excessive physical activity ( within 48 hour prior trial trial ) Clinically relevant laboratory abnormality ( except liver function test accord ChildPugh classification laboratory constellation parameter typically alter patient fulfil Child Pugh criterion ) include relevant electrolyte disturbance Serum albumin &lt; 20 g/L Hemoglobin &lt; 8 g/dL Inability comply dietary regimen study centre Subjects able understand comply protocol requirement , instruction protocolstated restriction Exclusion criterion specific study due know class side effect profile ß2 mimetics ( healthy hepatically impaired subject ) : Asthma history pulmonary hyperreactivity Hyperthyrosis Allergic rhinitis need treatment Clinically relevant cardiac arrhythmia For female subject ( healthy hepatically impaired ) : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception woman childbearing potential ( adequate contraception : e.g . sterilisation , intrauterine device oral contraception contain ethinyl estradiol ethinyl estradiol additional barrier method ) least 3 month prior participation study Inability maintain adequate contraception whole trial period . Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>